FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001461508> ?p ?o ?g. }

• W2001461508 endingPage "38579" @default.
• W2001461508 startingPage "38568" @default.
• W2001461508 abstract "Activation of RAW264.7 cells with a lipopolysaccharide specific for the TLR4 receptor, Kdo2-lipid A (KLA), causes a large increase in cellular sphingolipids, from 1.5 to 2.6 × 109 molecules per cell in 24 h, based on the sum of subspecies analyzed by “lipidomic” mass spectrometry. Thus, this study asked the following question. What is the cause of this increase and is there a cell function connected with it? The sphingolipids arise primarily from de novo biosynthesis based on [U-13C]palmitate labeling, inhibition by ISP1 (myriocin), and an apparent induction of many steps of the pathway (according to the distribution of metabolites and microarray analysis), with the exception of ceramide, which is also produced from pre-existing sources. Nonetheless, the activated RAW264.7 cells have a higher number of sphingolipids per cell because KLA inhibits cell division; thus, the cells are larger and contain increased numbers of membrane vacuoles termed autophagosomes, which were detected by the protein marker GFP-LC3. Indeed, de novo biosynthesis of sphingolipids performs an essential structural and/or signaling function in autophagy because autophagosome formation was eliminated by ISP1 in KLA-stimulated RAW264.7 cells (and mutation of serine palmitoyltransferase in CHO-LYB cells); furthermore, an anti-ceramide antibody co-localizes with autophagosomes in activated RAW264.7 cells versus the Golgi in unstimulated or ISP1-inhibited cells. These findings establish that KLA induces profound changes in sphingolipid metabolism and content in this macrophage-like cell line, apparently to produce sphingolipids that are necessary for formation of autophagosomes, which are thought to play important roles in the mechanisms of innate immunity. Activation of RAW264.7 cells with a lipopolysaccharide specific for the TLR4 receptor, Kdo2-lipid A (KLA), causes a large increase in cellular sphingolipids, from 1.5 to 2.6 × 109 molecules per cell in 24 h, based on the sum of subspecies analyzed by “lipidomic” mass spectrometry. Thus, this study asked the following question. What is the cause of this increase and is there a cell function connected with it? The sphingolipids arise primarily from de novo biosynthesis based on [U-13C]palmitate labeling, inhibition by ISP1 (myriocin), and an apparent induction of many steps of the pathway (according to the distribution of metabolites and microarray analysis), with the exception of ceramide, which is also produced from pre-existing sources. Nonetheless, the activated RAW264.7 cells have a higher number of sphingolipids per cell because KLA inhibits cell division; thus, the cells are larger and contain increased numbers of membrane vacuoles termed autophagosomes, which were detected by the protein marker GFP-LC3. Indeed, de novo biosynthesis of sphingolipids performs an essential structural and/or signaling function in autophagy because autophagosome formation was eliminated by ISP1 in KLA-stimulated RAW264.7 cells (and mutation of serine palmitoyltransferase in CHO-LYB cells); furthermore, an anti-ceramide antibody co-localizes with autophagosomes in activated RAW264.7 cells versus the Golgi in unstimulated or ISP1-inhibited cells. These findings establish that KLA induces profound changes in sphingolipid metabolism and content in this macrophage-like cell line, apparently to produce sphingolipids that are necessary for formation of autophagosomes, which are thought to play important roles in the mechanisms of innate immunity." @default.
• W2001461508 created "2016-06-24" @default.
• W2001461508 creator A5002672605 @default.
• W2001461508 creator A5003227513 @default.
• W2001461508 creator A5020444852 @default.
• W2001461508 creator A5032331390 @default.
• W2001461508 creator A5039839135 @default.
• W2001461508 creator A5046950791 @default.
• W2001461508 creator A5052788624 @default.
• W2001461508 creator A5059559405 @default.
• W2001461508 creator A5066354641 @default.
• W2001461508 creator A5073928063 @default.
• W2001461508 creator A5075453929 @default.
• W2001461508 date "2010-12-01" @default.
• W2001461508 modified "2023-10-16" @default.
• W2001461508 title "Kdo2-Lipid A, a TLR4-specific Agonist, Induces de Novo Sphingolipid Biosynthesis in RAW264.7 Macrophages, Which Is Essential for Induction of Autophagy" @default.
• W2001461508 cites W1534847945 @default.
• W2001461508 cites W1536374844 @default.
• W2001461508 cites W1557594417 @default.
• W2001461508 cites W1561776621 @default.
• W2001461508 cites W1874718130 @default.
• W2001461508 cites W1953668033 @default.
• W2001461508 cites W1966452335 @default.
• W2001461508 cites W1970504457 @default.
• W2001461508 cites W1970918529 @default.
• W2001461508 cites W1972297566 @default.
• W2001461508 cites W1972336737 @default.
• W2001461508 cites W1973406626 @default.
• W2001461508 cites W1976531450 @default.
• W2001461508 cites W1977581328 @default.
• W2001461508 cites W1977767269 @default.
• W2001461508 cites W1979365145 @default.
• W2001461508 cites W1982277787 @default.
• W2001461508 cites W1988327539 @default.
• W2001461508 cites W1991300803 @default.
• W2001461508 cites W1995461729 @default.
• W2001461508 cites W1999150533 @default.
• W2001461508 cites W1999160838 @default.
• W2001461508 cites W2001284886 @default.
• W2001461508 cites W2001956269 @default.
• W2001461508 cites W2003374952 @default.
• W2001461508 cites W2005565829 @default.
• W2001461508 cites W2008274598 @default.
• W2001461508 cites W2013199351 @default.
• W2001461508 cites W2018425859 @default.
• W2001461508 cites W2021239799 @default.
• W2001461508 cites W2022222076 @default.
• W2001461508 cites W2022497999 @default.
• W2001461508 cites W2024714308 @default.
• W2001461508 cites W2026356600 @default.
• W2001461508 cites W2028956758 @default.
• W2001461508 cites W2037320436 @default.
• W2001461508 cites W2044986630 @default.
• W2001461508 cites W2048333374 @default.
• W2001461508 cites W2061177902 @default.
• W2001461508 cites W2061700186 @default.
• W2001461508 cites W2064042544 @default.
• W2001461508 cites W2066829342 @default.
• W2001461508 cites W2068213179 @default.
• W2001461508 cites W2070908474 @default.
• W2001461508 cites W2071600529 @default.
• W2001461508 cites W2076666771 @default.
• W2001461508 cites W2079048898 @default.
• W2001461508 cites W2079962068 @default.
• W2001461508 cites W2082818188 @default.
• W2001461508 cites W2096308078 @default.
• W2001461508 cites W2104227437 @default.
• W2001461508 cites W2104501650 @default.
• W2001461508 cites W2111109862 @default.
• W2001461508 cites W2112156826 @default.
• W2001461508 cites W2112541364 @default.
• W2001461508 cites W2112733125 @default.
• W2001461508 cites W2114847797 @default.
• W2001461508 cites W2120648308 @default.
• W2001461508 cites W2126932701 @default.
• W2001461508 cites W2138882635 @default.
• W2001461508 cites W2138940299 @default.
• W2001461508 cites W2141165347 @default.
• W2001461508 cites W2142352722 @default.
• W2001461508 cites W2144508508 @default.
• W2001461508 cites W2150887806 @default.
• W2001461508 cites W2152567128 @default.
• W2001461508 cites W2153022420 @default.
• W2001461508 cites W2160845673 @default.
• W2001461508 cites W2164806733 @default.
• W2001461508 cites W2172201532 @default.
• W2001461508 cites W51578940 @default.
• W2001461508 cites W68089729 @default.
• W2001461508 doi "https://doi.org/10.1074/jbc.m110.170621" @default.
• W2001461508 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2992289" @default.
• W2001461508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20876532" @default.
• W2001461508 hasPublicationYear "2010" @default.
• W2001461508 type Work @default.
• W2001461508 sameAs 2001461508 @default.
• W2001461508 citedByCount "98" @default.
• W2001461508 countsByYear W20014615082012 @default.
• W2001461508 countsByYear W20014615082013 @default.
• W2001461508 countsByYear W20014615082014 @default.

• next